Description

• Product Overview: Ibruxen® is a Bruton’s tyrosine kinase (BTK) inhibitor containing Ibrutinib, used in the treatment of specific B-cell malignancies including chronic lymphocytic leukemia and mantle cell lymphoma.
• Composition: Ibrutinib INN 140 mg | Dosage Form: Capsule
• Pharmacological Class: Bruton’s Tyrosine Kinase (BTK) Inhibitor / Targeted Anticancer Therapy
• Mechanism of Action: Ibrutinib irreversibly inhibits BTK, a key enzyme in B-cell receptor signaling pathways, leading to inhibition of malignant B-cell proliferation and survival.
• Indications: Chronic lymphocytic leukemia (CLL) | Small lymphocytic lymphoma (SLL) | Mantle cell lymphoma (MCL) | Waldenström’s macroglobulinemia
• Dosage & Administration: As directed by oncology specialist only | Oral use | Usually taken once daily | Capsule should be swallowed whole with water
• Clinical Benefits: Slows progression of blood cancers | Reduces cancer cell growth | Improves disease control | Prolongs survival in eligible patients
• Contraindications: Hypersensitivity to Ibrutinib or any component of the formulation
• Precautions: Risk of bleeding | Risk of infection | Monitor blood counts regularly | Use cautiously in liver impairment | Avoid in pregnancy unless clearly necessary
• Drug Interactions: May interact with strong CYP3A inhibitors/inducers, anticoagulants, and antiplatelet agents
• Special Populations: Not recommended during pregnancy and lactation unless clearly advised by oncologist | Elderly use under strict supervision
• Adverse Effects: Diarrhea | Fatigue | Bruising | Neutropenia | Anemia | Risk of bleeding | Atrial fibrillation (rare)
• Storage Conditions: Store below 30°C | Protect from light and moisture | Keep out of reach of children
• Packaging: Capsule blister pack
• Manufacturer: Everest Pharmaceutical Ltd.